Harris Technology surges as profit upgraded by more than 50%

|

Published 24-JUN-2020 10:55 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in diversified tech enterprise and personal protective equipment distributor, Harris Technology Group (ASX:HT8) opened 35% higher on Wednesday morning after the company upgraded its profit guidance.

In May, the company forecast revenues of $13 million and a pre-tax profit of $700,000 for fiscal 2020.

However, just one week out from year-end, management has been able to substantially upgrade profit guidance to $1.1 million.

Importantly, this is a significant turnaround from the fiscal 2019 pre-tax loss of $732,000.

Year-on-year comparative figures also highlight the impressive top-line growth that the company is achieving with revenues up from $9 million in fiscal 2019 to a projected $13.5 million in fiscal 2020.

The revised profit and revenue forecasts come on the back of confirmation of strong sales in the month of May and June 2020 to date.

Commenting on the key drivers behind the group’s improvement, managing director Garrison Huang said, “We are pleased by the substantial profit turnaround for FY2020, which has been further upgraded since our previous forecast announced on 26 May 2020.

‘’Strong sales growth continues in our IT division, driven by our strategy of product diversification including mobile accessories, IT consumable products such as inks and toners and gaming products.

“We are also looking to further build on the success of our personal protective equipment (PPE) division, Pro-Hygiene, in the year ahead.”

Anti-virus software emerging as a key source of growth in 2021

Of note, sales of antivirus software have increased as a result of HT8 undertaking a number of marketing campaigns with ESET Australia.

These campaigns included free offers to customers designed to assist them during the COVID-19 pandemic.

Harris subsidiary, APCA Trading, is a platinum partner of ESET Australia, one of the leading antivirus end point vendors in the world.

The company expects that sales of ESET internet security and anti-virus software will increase in coming months.

Harris Technology's broader range of technology products includes HP, Microsoft, Adobe, Lenovo, Brother, Toshiba, Samsung, Asus and Sony, highlighting its strong and trusted relationships with leading brands in the field.

The company has successfully established its own e-commerce site, as well as having a presence on Amazon Australia, Catch, Kogan and eBay.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X